| Identification | Back Directory | [Name]
Pyrazolo[4,3-d][1,3]benzodiazepine, 5-(2,6-difluorophenyl)-9-fluoro-2,4-dihydro-8-(4-pyridazinyl)- | [CAS]
2629192-96-5 | [Synonyms]
LRRK2/NUAK1/TYK2-IN-1
Pyrazolo[4,3-d][1,3]benzodiazepine, 5-(2,6-difluorophenyl)-9-fluoro-2,4-dihydro-8-(4-pyridazinyl)-
5-(2,6-Difluorophenyl)-9-fluoro-8-(pyridazin-4-yl)-2,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine | [Molecular Formula]
C20H11F3N6 | [MOL File]
2629192-96-5.mol | [Molecular Weight]
392.34 |
| Hazard Information | Back Directory | [Uses]
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research[1]. | [IC 50]
Tyk2; NUAK1 | [References]
[1] Roland Koestler, et al. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease. Patent WO2021048618A1. |
|
|